Evolus, Inc. 2017 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: Evolus, Inc.
Reporting Period: Fiscal year ended December 31, 2017
Business Overview: Evolus is a medical aesthetics company focused on the self-pay market. Its sole product candidate is DWP-450 (PrabotulinumtoxinA), an injectable 900 kDa botulinum toxin type A complex designed to treat moderate to severe glabellar lines (frown lines). The company has completed its clinical development program and submitted regulatory filings to the FDA (BLA), EMA (MAA), and Health Canada (NDS).
Regulatory Status: The FDA issued a PDUFA date of May 15, 2018. Decisions from the EMA and Health Canada were expected in the second half of 2018. The company had no commercial revenue as of the reporting date.
Key Financial Metrics
| Metric | 2017 | 2016 | 2015 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(4.5) million | $(20.1) million | $(31.1) million |
| Total Operating Expenses | $11.7 million | $20.0 million | $31.0 million |
| Cash and Cash Equivalents (Year End) | $0 | $0 | $0 |
| Accumulated Deficit | $(75.5) million | $(66.8) million | $(46.7) million |
| Net Cash Used in Operating Activities | $(13.0) million | $(13.3) million | $(36.4) million |
Note: The company had no cash on hand as of December 31, 2017. Operations were funded entirely by related party borrowings from its parent, ALPHAEON Corporation. Subsequent to year-end, the company completed an IPO in February 2018, raising approximately $53.3 million in net proceeds.
Material Changes vs. Prior Period
- Expense Reduction: Net loss decreased significantly from $20.1 million in 2016 to $4.5 million in 2017. This was primarily driven by a $5.9 million decrease in Research and Development (R&D) expenses, attributed to the completion of Phase III clinical trials in 2016. General and Administrative (G&A) expenses also decreased by $2.2 million due to reduced allocations from ALPHAEON.
- Tax Benefit: The company recorded a significant income tax benefit of $7.3 million in 2017, compared to a $0.1 million expense in 2016. This was largely due to the enactment of the Tax Cuts and Jobs Act (TCJA), which reduced the U.S. federal corporate tax rate, resulting in a revaluation of deferred tax assets.
- Balance Sheet Restructuring: As of December 31, 2017, the company recorded a $138.7 million "Note obligation" representing a joint and several liability guarantee for ALPHAEON's convertible notes. This liability, along with related party borrowings of $72.6 million, was resolved upon the completion of the IPO in February 2018.
Outlook, Risks, and Contingencies
- Commercialization Plan: Upon FDA approval, Evolus plans to launch DWP-450 in the U.S. with a specialty sales force of approximately 65 representatives, growing to 150 over time. The strategy focuses on an aesthetic-only, self-pay market to allow for pricing flexibility not available to competitors with therapeutic indications.
- Key Risks:
- Regulatory Approval: The company's viability depends entirely on the approval of DWP-450. Delays or denial by the FDA, EMA, or Health Canada would be catastrophic.
- Manufacturing: DWP-450 is manufactured exclusively by Daewoong Pharmaceuticals in South Korea. The FDA and MHRA issued inspectional observations (Form 483) regarding the facility in late 2017/early 2018. While Daewoong has responded with corrective action plans, failure to resolve these could delay approval.
- Litigation: Medytox, Inc. has filed lawsuits alleging trade secret misappropriation regarding the bacterial strain used in DWP-450. Medytox also filed a Citizen Petition with the FDA seeking to delay approval. The outcome is uncertain and could result in injunctions or loss of rights.
- Liquidity: Prior to the IPO, the company had no cash. Future funding requirements depend on the timing of regulatory approval and commercialization success.
- Contingent Obligations: The company has assumed payment obligations to "Evolus contributors" (former shareholders) totaling an estimated $55.7 million as of the IPO closing, including a $20 million promissory note and future royalties. Additionally, there is a potential $1.0 million liquidated damages obligation to Clarion Medical Technologies if Canadian approval is not received by October 31, 2018.
Investor Verification Checklist
- Regulatory Decision: Verify the final decision status of the FDA BLA (PDUFA date May 15, 2018) and the EMA/Health Canada applications.
- Manufacturing Compliance: Confirm that the FDA and MHRA have accepted Daewoong's corrective action plans regarding the Form 483 observations and that the facility is approved for commercial production.
- Litigation Status: Monitor the progress of the Medytox litigation and the FDA's response to the Citizen Petition, as these pose existential threats to the product launch.
- Capital Runway: Assess the utilization of the $53.3 million IPO proceeds against the projected costs of building the sales force and commercial infrastructure.
- Related Party Transactions: Review the terms of the services agreement with ALPHAEON and the specific milestones triggering payments to the Evolus contributors.